Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on Tuesday, May 4, 2021
April 27 2021 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that it
will report first quarter 2021 financial results and provide a
corporate update before market open on Tuesday, May 4, 2021. Jounce
Therapeutics’ management team will host a live conference call and
webcast at 8:00 a.m. ET.
Conference Call and WebcastTo access the
conference call, please dial (866) 916-3380 (domestic) or (210)
874-7772 (international) and refer to conference ID 1389694. The
live webcast can be accessed under “Events & Presentations” in
the Investors and Media section of the company’s website at
www.jouncetx.com. The webcast will be archived and made available
for replay on the company’s website approximately two hours after
the call and will be available for 30 days thereafter.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
currently has multiple development stage programs ongoing while
simultaneously advancing additional early-stage assets from its
robust discovery engine based on its Translational Science
Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2
(ILT4) receptor antagonist shown to reprogram immune-suppressive
tumor associated macrophages to an anti-tumor state in preclinical
studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a
monotherapy and in combination with JTX-4014, Jounce’s internal
PD-1 inhibitor, or pembrolizumab is currently enrolling patients
with advanced solid tumors. Jounce’s most advanced product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS, and is currently being studied in the SELECT Phase
2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use
in the INNATE and SELECT trials and with Jounce’s broader pipeline.
Additionally, Jounce exclusively licensed worldwide rights to
JTX-1811, a monoclonal antibody targeting CCR8 and designed to
selectively deplete T regulatory cells in the tumor
microenvironment, to Gilead Sciences, Inc.
Investor and Media Contacts:Malin DeonJounce
Therapeutics, Inc.+1-857-259-3843mdeon@jouncetx.com
Mark YoreJounce Therapeutics, Inc.+1-857-200-1255
myore@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024